KRYSTAL-1 is a Phase 1/2 clinical trial investigating the selective KRAS G12C inhibitor adagrasib (MRTX849) in patients with advanced solid tumors.
🔬 General Information
Drug: Adagrasib (MRTX849)
Trial Phase: Phase 1/2
Target Mutation: KRAS G12C
Tumor Types Studied:
Colorectal Cancer (CRC)
Non-Small Cell Lung Cancer (NSCLC)
Other solid tumors
🧪 Results in Colorectal Cancer (CRC)
Adagrasib Monotherapy
Objective Response Rate (ORR): 19%
Median Progression-Free Survival (PFS): 5.6 months
Median Overall Survival (OS): 19.8 months
Adagrasib + Cetuximab Combination
ORR: 34%
Disease Control Rate (DCR): 85.1%
Median Duration of Response: 5.8 months
Median PFS: 6.9 months
Median OS: 15.9 months
Grade 3–4 Treatment-Related Adverse Events: 27.7%
Grade 5 Events: None reported
🫁 Results in Non-Small Cell Lung Cancer (NSCLC)
ORR: 43%
Median Duration of Response: 8.5 months
Median PFS: 6.5 months
Median OS: 12.6 months
✅ Regulatory Update
In June 2024, the FDA granted accelerated approval for the combination of adagrasib + cetuximab in patients with previously treated KRAS G12C-mutant metastatic CRC.